Progentec Diagnostics, a provider in diagnostic and digital technologies for the management of autoimmune diseases, launched a collaborative study with GSK aimed at identifying individuals at risk of developing lupus and guiding them through a virtual diagnostic journey.
The PROACTIVE study aims to empower individuals to take control of their health by providing them with a comprehensive and personalized approach to help them evaluate their lupus symptoms, the company says.
Progentec has brought together advanced technologies and patient engagement initiatives to identify individuals at risk of lupus and other connective tissue disorders. The PROACTIVE study will guide individuals at risk of developing lupus through a virtual diagnostics journey comprising a series of online assessments, advanced biomarker tests, virtual consultations with primary care and rheumatology specialists. The virtual diagnostic journey is designed to be convenient, accessible, and user-friendly, with the goal of providing individuals with the information and support they need to manage their condition effectively.
“We are excited to launch this transformative study, which has the potential to change the way lupus is diagnosed and managed,” says Eldon Jupe, PhD, principal investigator of PROACTIVE. “We believe that this study will not only contribute substantially to our understanding of lupus during its early phases but also provide much needed answers to persons who experience unexplained symptoms attributable to lupus.”
